In addition, changes in PSMA-TV and SUV were also associated with PSA response in metastatic PCa patients undergoing various systemic therapies (radium-223, taxane-based chemotherapy, abiraterone, enzalutamide) [9]. Here, FOLH1 is linked to posterior cortical atrophy.